PD
BDTX icon

Point72 (DIFC)’s Black Diamond Therapeutics BDTX Stock Holding History

Point72 (DIFC)’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$544 Sell
143
-7,081
-98% -$20.7K ﹤0.01% 1084
2025
Q2 		$17.9K Buy
+7,224
New +$13.9K ﹤0.01% 1240
2025
Q1 		– Sell
-23,021
Closed -$49.3K – 1674
2024
Q4 		$49.3K Buy
23,021
+18,095
+367% +$51.9K ﹤0.01% 1127
2024
Q3 		$21.4K Buy
+4,926
New +$26.8K ﹤0.01% 1201

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 (DIFC)'s BDTX Position: Q3 2025 in Review

Point72 (DIFC) reduced its Black Diamond Therapeutics (BDTX) stake by 98% in Q3 2025, selling an estimated $20.7K and leaving 143 shares worth $544. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Point72 (DIFC) first reported a position in BDTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $49.3K in Q4 2024. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

  • Point72 (DIFC) held 143 shares of Black Diamond Therapeutics worth $544 as of Q3 2025.
  • Point72 (DIFC) sold 7,081 Black Diamond Therapeutics shares in Q3 2025, an estimated $20.7K.
  • Black Diamond Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1084 holding.
  • Point72 (DIFC) first reported a position in Black Diamond Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Point72 (DIFC)'s Black Diamond Therapeutics position peaked at $49.3K in Q4 2024.
  • 91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.